Trial Profile
Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of MCS in Treating Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs MCS 2 (Primary)
- Indications Benign prostatic hyperplasia
- Focus Registrational; Therapeutic Use
- Sponsors Health Ever Bio-Tech
- 27 Nov 2015 New trial record